Why Did IGM Biosciences Shares Advance Today?

IGM Biosciences Inc IGMS has progressed two Phase 1 trials evaluating IGM-6268, an anti-SARS-CoV-2 IgM monoclonal antibody, to treat and prevent infection COVID-19. 

  • The first Phase 1 trial is a single (SAD) and multiple (MAD) ascending dose study to assess IGM-6268 administered intranasally in healthy volunteers. 
  • The first two dose cohorts of healthy volunteers have been cleared in the U.S., and data from the study are expected in 1H of 2022.
  • The second Phase 1a/1b trial in South Africa assesses IGM-6268 administered intranasally first in healthy volunteers, once an appropriate dose cohort has been cleared, in outpatients with mild to moderate COVID-19. 
  • Data from the study are expected in mid-2022.
  • IGM-6268 is an engineered IgM antibody that specifically targets the receptor-binding domain of the SARS-CoV-2 spike protein. 
  • Price Action: IGMS shares are trading 9.52% higher at $18.86 during the market session on the last check Wednesday.

Posted In: BriefsCOVID-19 CoronavirusPhase 1 Trialwhy it's movingBiotechNewsHealth CareSmall CapMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.